A phase IIa randomized, double-blind, parallel-groups, placebo controlled clinical trial to study the efficacy and safety of MK0724 [arundic acid] intravenous infusion on the amelioration of neurological damage and recovery middle cerebral artery ischemic stroke

Trial Profile

A phase IIa randomized, double-blind, parallel-groups, placebo controlled clinical trial to study the efficacy and safety of MK0724 [arundic acid] intravenous infusion on the amelioration of neurological damage and recovery middle cerebral artery ischemic stroke

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs Arundic acid (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 03 Nov 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 01 Feb 2009 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 16 Nov 2008 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top